Accessibility Menu
BioAdaptives logo

BioAdaptives(OTC) BDPT

Market Cap$34.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year-92%
1 Month+167%
$0.00
-14.29%
-0.00Today
BioAdaptives last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-10
BioAdaptives stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-46.67%USD 0.002026-08-03
1 month+166.67%USD 0.002026-07-10
3 month-78.18%USD 0.012026-05-11
Year to date-89.14%USD 0.022025-12-30
1 year-92.42%USD 0.032025-08-08
3 year-99.56%USD 0.542023-08-11
5 year-99.96%USD 5.402021-08-11
Since inception-99.99%USD 33.002016-06-01

BioAdaptives Financials at a Glance

Market Cap

$34.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$23.79K

Net Income (TTM)

-$1.47M

EPS (TTM)

-$0.13

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

0.67 (Low)

Price

$0.00

Volume

24,559,328

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.07

Estimated Earnings Date

N/A

BDPT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioAdaptives

BioAdaptives makes plant-based supplements and devices for people and animals. Its products help with pain, breathing, and general wellness. Customers include pet owners, athletes, and those seeking natural health support.

What’s in the Bottle? Products and Services

  • Human Supplements: Dietary products for cognitive health, pain relief, and relaxation; targets adults seeking natural wellness.
  • Animal Supplements: Canine and equine formulas for pet owners and trainers; supports joint, immune, and overall animal health.
  • Medical Device: Lung Flute, a lung health device for people with breathing issues; sold to individuals and clinics.
  • Direct-to-Consumer Sales: Products sold online and through telehealth partners.
  • All-in-One Formulas: Combined vitamins, minerals, and botanicals for both humans and animals; appeals to those seeking comprehensive support.

Growth and Expansion: The Road So Far

  • Acquired the Lung Flute device in 2024, entering the medical device market.
  • Launched PawPa Regen dog treats in 2025, expanding animal product lines.
  • Formed partnerships with telehealth and affiliate marketing platforms since 2024 to boost online sales.
  • Expanded distribution to Amazon and hospitality sectors for pet products in 2025.
  • Reformulated and launched new human supplements (including Xcellara and Wynovia) in 2025, with MyndMed and Zeranovia expected to launch late 2025 following pre-launch and clinical trial phases.

What Makes BioAdaptives Stand Out?

The company focuses on natural ingredients and research-driven product development. It combines human and animal health offerings under one brand. Its direct-to-consumer model uses digital marketing and telehealth partnerships for reach.

Five Things You Need to Know

  • Q2 2025 revenue was $3,219, up 376.9% from Q2 2024.
  • Gross margin in Q2 2025 was 33.0% on $3,219 revenue.
  • Net loss for Q2 2025 was $157,914, improved 13.7% from Q2 2024.
  • Cash as of June 30, 2025, was $210,582, up from $137,470 at year-end 2024.

Bottom Line

BioAdaptives has diversified into both human and animal wellness with new products and channels. The company faces ongoing financial challenges but continues to adapt its offerings and partnerships.

AI Generated • Apr 16, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

1

CEO

James Keener

Website

www.bioadaptives.com

Headquarters

Las Vegas, NV 89128, US

BDPT Financials

Key Financial Metrics (TTM)

Gross Margin

66.66%

Operating Margin

-4159.98%

Net Income Margin

-6186.89%

Return on Equity

85.75%

Return on Capital

N/A

Return on Assets

-1082.75%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$34.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.01M

Volume

24.56M

Avg. Volume

10.61M

Financials (TTM)

Gross Profit

$15.86K

Operating Income

-$989.74K

EBITDA

-$1.24M

Operating Cash Flow

-$502.96K

Capital Expenditure

-$18.00K

Free Cash Flow

-$520.96K

Cash & ST Invst.

$73.61K

Total Debt

$456.31K

BioAdaptives Performance Analysis

BioAdaptives annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 17,176-13.1%
20232023-12-31USD 28,56566.3%
20242024-12-31USD 12,669-55.6%
20252025-12-31USD 18,27844.3%
BioAdaptives sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3043.9%
Q42025-12-31125.1%
Q12026-03-31-47.1%
BioAdaptives annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.27-72.8%
20232023-12-31USD -0.19-85.0%
20242024-12-31USD -0.05-71.3%
20252025-12-31USD -0.15182.8%
BioAdaptives sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3023.9%
Q32025-09-30-123.5%
Q42025-12-31-100.8%
Q12026-03-3187.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$5.51K

N/A

Gross Profit

$4.11K

N/A

Gross Margin

74.59%

N/A

Market Cap

$34.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$34.20K

N/A

Employees

1

N/A

Net Income

-$111.09K

+43.6%

EBITDA

-$21.83K

+91.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$73.61K

+86.0%

Total Debt

$456.31K

+33.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$42.97K

+5.9%

Long Term Debt

$0.00

N/A

Short Term Debt

$456.31K

+33.0%

Return on Assets

-10.83%

N/A

Return on Invested Capital

46.33%

N/A

Free Cash Flow

-$84.84K

+13.3%

Operating Cash Flow

-$84.84K

+13.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BSFCBlue Star Foods Corp.
$0.00+25.00%
KOMOFKomo Plant Based Foods Inc.
$0.00+0.00%
DEWMDewmar International BMC, Inc.
$0.00+0.00%
AJYGAJ1G, Inc.
$0.04+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About BDPT

What is the current price of BioAdaptives?

BioAdaptives is trading at $0.00 per share.

What is the 52-week range for BioAdaptives?

Over the past 52 weeks, BioAdaptives has traded between $0.00 and $0.07.

How much debt does BioAdaptives have?

As of the most recent reporting period, BioAdaptives reported total debt of $456.31K.

How much cash does BioAdaptives have on hand?

BioAdaptives reported $73.61K in cash and cash equivalents in its most recent financial results.

What is BioAdaptives’s dividend yield?

BioAdaptives does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services